Efficacy and safety of ruxolitinib in regularly transfused patients with thalassemia: Results from a phase 2a study

Efficacy and safety of ruxolitinib in regularly transfused patients with thalassemia: Results from a phase 2a study

Saved in:

Bibliographic Details
Main Authors:	Ali T. Taher, Zeynep Karakas, Elena Cassinerio, Noppadol Siritanaratkul, Antonis Kattamis, Aurelio Maggio, Stefano Rivella, Norbert Hollaender, Bruyere Mahuzier, Brian Gadbaw, Yesim Aydinok
Other Authors:	American University of Beirut Medical Center
Format:	Letter
Published:	2019
Subjects:	Biochemistry, Genetics and Molecular Biology Immunology and Microbiology Medicine
Online Access:	https://repository.li.mahidol.ac.th/handle/123456789/45268
Tags:	Add Tag No Tags, Be the first to tag this record!
Institution:	Mahidol University

Similar Items

Revisiting the non-transfusion-dependent (NTDT) vs. transfusion-dependent (TDT) thalassemia classification 10 years later
by: Khaled M. Musallam, et al.
Published: (2022)

Optimising iron chelation therapy with deferasirox for non-transfusion-dependent thalassaemia patients: 1-year results from the THETIS study
by: Ali T. Taher, et al.
Published: (2018)

Approaching low liver iron burden in chelated patients with non-transfusion-dependent thalassemia: The safety profile of deferasirox
by: Ali T. Taher, et al.
Published: (2018)

Current approach to iron chelation in children
by: Yesim Aydinok, et al.
Published: (2018)

Deferasirox demonstrates a dose-dependent reduction in liver iron concentration and consistent efficacy across subgroups of non-transfusion-dependent thalassemia patients
by: Ali T. Taher, et al.
Published: (2018)

Deferasirox effectively reduces iron overload in non-transfusion-dependent thalassemia (NTDT) patients: 1-year extension results from the THALASSA study
by: Ali T. Taher, et al.
Published: (2018)

Changing patterns in the epidemiology of β-thalassemia
by: Antonis Kattamis, et al.
Published: (2020)

Quality of life in patients with β-thalassemia: A prospective study of transfusion-dependent and non-transfusion-dependent patients in Greece, Italy, Lebanon, and Thailand
by: Maria Domenica Cappellini, et al.
Published: (2020)

Improving outcomes and quality of life for patients with transfusion-dependent β-thalassemia: recommendations for best clinical practice and the use of novel treatment strategies
by: Ali T. Taher, et al.
Published: (2022)

Non-transfusion-dependent thalassemia: A complex mix of genetic entities yet to be fully discovered
by: Paolo Ricchi, et al.
Published: (2018)

When to consider transfusion therapy for patients with non-transfusion-dependent thalassaemia
by: A. T. Taher, et al.
Published: (2018)

Deferasirox reduces iron overload significantly in nontransfusion-dependent thalassemia: 1-Year results from a prospective, randomized, double-blind, placebo-controlled study
by: Ali T. Taher, et al.
Published: (2018)

Combined pulmonary tuberculosis with pulmonary and pleural cryptococcosis in a patient receiving ruxolitinib therapy
by: Akarawut Kasemchaiyanun, et al.
Published: (2022)

Geographical variations in current clinical practice on transfusions and iron chelation therapy across various transfusion-dependent anaemias
by: Vip Viprakasit, et al.
Published: (2018)

LEE011 and ruxolitinib: A synergistic drug combination for natural killer/T-cell lymphoma (NKTCL)
by: Hee, Y.T, et al.
Published: (2020)

Effects of deferasirox-deferoxamine on myocardial and liver iron in patients with severe transfusional iron overload
by: Yesim Aydinok, et al.
Published: (2018)

MRI for the diagnosis of cardiac and liver iron overload in patients with transfusion-dependent thalassemia: An algorithm to guide clinical use when availability is limited
by: Vip Viprakasit, et al.
Published: (2019)

Cryptococcal fungemia and Mycobacterium haemophilum cellulitis in a patient receiving ruxolitinib: a case report and literature review
by: Naruemit Sayabovorn, et al.
Published: (2022)

Psychometric evaluation of the NTDT-PRO questionnaire for assessing symptoms in patients with non-transfusion-dependent beta-thalassaemia
by: Taher A.T.
Published: (2023)

Ruxolitinib Treatment in an Adolescent With Chronic Graft-Versus-Host Disease Mimicking Eosinophilic Gastrointestinal Disorders: A Case Report
by: Songpon Getsuwan, et al.
Published: (2022)

Ruxolitinib Treatment in an Adolescent With Chronic Graft-Versus-Host Disease Mimicking Eosinophilic Gastrointestinal Disorders: A Case Report
by: Getsuwan S.
Published: (2023)

A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent β-Thalassemia
by: M. Domenica Cappellini, et al.
Published: (2020)

A phase 3 trial of luspatercept in patients with transfusion-dependent β-thalassemia
by: M. Domenica Cappellini, et al.
Published: (2020)

Inter-site validations of the Pixel-Wise method for cardiac T2* analysis in transfusion-dependent Thai thalassemia patients.
by: Pairash Saiviroonporn, et al.
Published: (2018)

Tailoring iron chelation by iron intake and serum ferritin: The prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias
by: Maria Domenica Cappellini, et al.
Published: (2018)

Treating iron overload in patients with non-transfusion-dependent thalassemia
by: Ali T. Taher, et al.
Published: (2018)

Luspatercept for the treatment of anaemia in non-transfusion-dependent β-thalassaemia (BEYOND): a phase 2, randomised, double-blind, multicentre, placebo-controlled trial
by: Taher A.T.
Published: (2023)

Curcuminoids supplementation ameliorates iron overload, oxidative stress, hypercoagulability, and inflammation in non-transfusion-dependent β-thalassemia/Hb E patients
by: Suneerat Hatairaktham, et al.
Published: (2022)

Identification and key management of non-transfusion-dependent thalassaemia patients: Not a rare but potentially under-recognised condition
by: Vip Viprakasit, et al.
Published: (2018)

Identification and key management of non-transfusion-dependent thalassaemia patients: not a rare but potentially under-recognised condition
by: Vip Viprakasit, et al.
Published: (2017)

Iron chelation therapy for non-transfusion-dependent thalassemia (NTDT): A status quo
by: Ali T. Taher, et al.
Published: (2018)

Hydroxyurea for reducing blood transfusion in non-transfusion dependent beta thalassaemias
by: Wai Cheng Foong, et al.
Published: (2018)

Hydroxyurea for reducing blood transfusion in non-transfusion dependent beta thalassaemias
by: Wai Cheng Foong, et al.
Published: (2018)

The mortality of exchange transfusions
by: Tan, K.L., et al.
Published: (2016)

The effectiveness of exchange transfusions
by: Tan, K.L., et al.
Published: (2016)

Investigation procedures for transfusion reactions
by: P. Chiewsilp
Published: (2018)

Assessment on the satisfaction of hospital using centralized blood transfusion service: Case study of Hanoi Blood Transfusion Center
by: Ho, Thi Hai Van
Published: (2017)

Exchange transfusion in severe falciparum malaria
by: Somprasong Gulprasutdilog, et al.
Published: (2018)

Exchange transfusion in severe falciparum malaria
by: S. Gulprasutdilog, et al.
Published: (2018)

Deferasirox for up to 3 years leads to continued improvement of myocardial T2* in patients with β-thalassemia major
by: Dudley J. Pennell, et al.
Published: (2018)